More than 250 willing candidates will be used for the stage II trials. Advertisement for the same will take place as soon as a deal is strike by the two parties.

PGIMER or The Post Graduate Institute of Medical Education and Research will soon start the Phase II preliminary of Oxford Covid-19 vaccine - Covishield. This testing is expected to begin most probably in the early stage of September.

After receiving endorsement from the ethical committee, the institute is anticipating for tripartite arrangement between the Indian Council of Medical Research (ICMR) and Serum Institute of India (SII) inside the following two days.

Dr Gupta said that the consenting to of the arrangement would be trailed by a site review and hands-on preparing of a 16-part staff chose to lead the preliminary study by Clinical Research Organization (CRO).

Dr Gupta further added "The staff conducting the trial includes nine investigators who are faculty members of different departments like general medicine, microbiology, pathology, and rest are statistical assistants."

More than 250 willing candidates will be used for the stage II trials. Advertisement for the same will take place as soon as a deal is strike by the two parties.

On the related topic, Dr Gupta said "Our commitment is 253 candidates, and to get that figure, we would at least have to screen 350 volunteers.”

The vaccine will be given in two portions to the candidates, each portion maintaining a span of one month.

"0.5 ml of each dose would be given to the candidates first. It would be repeated after 28 days, and then the candidates would be observed for further two to four weeks." she added

For the tests to be held it is essential for the applicants to not be below 18 years of age, no hidden ailment and they ought not have contracted Covid-19 as of now.

She further said "We have kept open the upper age limit to study heterogeneity of the vaccine. It is observed that the vaccine enables the creation of varied antibodies depending on age. We would also include this factor in our study."